Complement expression on astrocytes and astrocytoma cell lines: Failure of complement regulation at the C3 level correlates with very low CD55 expression

Journal of Neuroimmunology

Volumn 71, Issue 1-2, 1996, Pages 97-106

  Spiller, O Brad ^a   Moretto, Giuseppe ^b   Kim, Seung U ^b   Morgan, B Paul ^a   Devine, Dana V ^c,d  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Canadian Red Cross Society   (Canada)

Author keywords

astrocyte; CD46; CD55; CD59; complement; glioma

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN;

ARTICLE; ASTROCYTE; ASTROCYTOMA; CELL LINE; FETUS; GLIOMA; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL;

ANTIGENS, CD; ANTIGENS, CD46; ANTIGENS, CD55; ANTIGENS, CD59; ASTROCYTES; ASTROCYTOMA; CELLS, CULTURED; COMPLEMENT C3; COMPLEMENT INACTIVATOR PROTEINS; FETUS; FLUORESCEINS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; RNA, MESSENGER;

EID: 0030560852     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(96)00136-1     Document Type: Article

References (43)

1. Akiyama H., Yamada T., Kawamata T., McGeer P.L. Association of amyloid P component with complement proteins in neurologically diseased brain tissue. Brain Res. 548:1991;349-352.
2. Andrews J.M., Thompson J.A., Pysher T.J., Walker M.L., Hammond M.E. Chronic encephalitis, epilepsy, and cerebrovascular immune complex deposits. Ann. Neurol. 28:1990;88-90.
3. Barnum S.R., Jones J.L., Benveniste E.N. Interleukin-1 and tumor necrosis factor-mediated regulation of C3 gene expression in human astroglioma cells. Glia. 7:1993;225-236.
4. Compston D.A.S., Morgan B.P., Campbell A.K., Wilkins P., Cole G., Thomas N.D., Jasani B. Immunocytochemical localization of the terminal complement complex in multiple sclerosis. Neuropathol. Appl. Neurobiol. 15:1989;307-316.
5. Coyne K.E., Hall S.E., Thompson E.S., Arce M.A., Kinoshita T., Fujita T., Anstee D.J., Rosse W., Lublin D.M. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay-accelerating factor. J. Immunol. 149:1991;2906-2913.
6. Devine D.V. The regulation of complement on cell surfaces. Trans. Med. Rev. 5:1991;123-131.
7. Eikelenboom P., Hack C.E., Rozemuller J.M., Stam F. Complement activation in amyloid plaques in Alzheimer's dementia. Virchows Arch. (Cell. Pathol.). 56:1989;259-262.
8. Finberg R.W., White W., Nicholson-Weller A. Decay-accelerating factor expression on either effector or target cells inhibits cytotoxicity by human natural killer cells. J. Immunol. 149:1992;2055-2060.
9. Fujita T., Inoue T., Ogawa K., Iida K., Tamura N. The mechanism of action of decay-accelerating factor (CD55). J. Exp. Med. 166:1987;1221-1228.
10. Gasque P., Julen N., Ischenko A.M., Picot C., Mauger C., Chauzy C., Ripoche J., Fontaine M. Expression of complement components of the alternative pathway by glioma cell lines. J. Immunol. 149:1992;1381-1387.
11. Gasque P., Fontaine M., Morgan B.P. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cell lines. J. Immunol. 154:1995;4726-4733.
12. Gay D., Esiri M. Blood-brain barrier damage in acure multiple sclerosis plaques. Brain. 114:1991;557-572.
13. Gordon D.L., Avery V.M., Adrian D.L., Sadlon T.A. Detection of complement protein mRNA in human astrocytes by the polymerase chain reaction. J. Neurosci. Meth. 45:1992;191-197.
14. Gordon D.L., Sadlon T.A., Wesselingh S.L., Russel S.M., Johnstone R.W., Purcell D.F.J. Human astrocytes express membrane cofactor protein (CD46), a regulator of complement activation. J. Neuroimmunol. 36:1992;199-208.
15. Gordon D.L., Sadlon T., Hefford C., Adrian D. Expression of CD59, a regulator of the membrane attack complex of complement, on human astrocytes. Mol. Brain Res. 18:1993;335-338.
16. Ishii T., Haga S. Complement, microglial cells and amyloid fibril formation. Res. Immunol. 143:1992;614-616.
17. Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 140:1992;691-707.
18. Kemp P.A., Spragg J.H., Brown J.C., Morgan B.P., Gunn C.A., Taylor P.A. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies. J. Clin. Lab. Immunol. 37:1992;147-162.
19. Kinoshita T., Medof M.E., Silber R., Nussenzweig V. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J. Exp. Med. 162:1985;75-92.
20. Kojima A., Iwata K., Seya T. Membrane cofactor protein (CD46) protects cells predominantly from alternative complement pathway-mediated C3 fragment deposition and cytolysis. J. Immunol. 151:1993;1519-1524.
21. 2 synthesis. J. Clin. Invest. 71:1983;1240-1248.
22. McGeer P.L., McGeer E.G. Complement proteins and complement inhibitors in Alzheimer's disease. Res. Immunol. 143:1992;621-623.
23. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett. 107:1989;341-336.
24. McGeer P.L., Walker D.G., Akiyama H., Kawamata T., Guan A.L., Parker C.J., Okada N., McGeer E.G. Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res. 544:1991;315-319.
25. McGeer P.L., Kawamata T., Walker D.G. Distribution of clusterin in Alzheimer brain tissue. Brain Res. 579:1992;337-341.
26. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., Lachmann P.G. Human Protectin (CD59), and 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunol. 71:1990;1-9.
27. Medof M.E., Kinoshita T., Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (CD55) into their membranes. J. Exp. Med. 160:1984;1558-1578.
28. Morgan B.P. Isolation and characterization of the complement-inhibiting protein CD59 antigen from platelet membranes. Biochem. J. 282:1992;409-413.
29. Nicholson-Weller A., Burge J., Fearon D.T., Weller P.F., Austen K.F. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J. Immunol. 129:1982;184-189.
30. Pangburn, M.K. (1986) Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases. 136, 2216-2221.
31. Powers J.M., Liu Y., Moser A.B., Moser H.W. The inflammatory myelinopathy of adreno-leukodystrophy: Cells, effector molecules, and pathogenetic implications. J. Neuropath. Exp. Neurol. 51:1992;630-643.
32. Rollins S.A., Zhao J., Ninomiya H., Sims P.J. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. J. Immunol. 146:1991;2345-2351.
33. Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., Lieberburg I. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 89:1992;10016-10020.
34. Rogers J., Schultz J., Brachova L., Lue L.-F., Webster S., Bradt B., Cooper N.R., Moss D.E. Complement activation and beta-amyloid-mediated neurotoxicity in Alzheimer's disease. Res. Immunol. 143:1992;624-630.
35. Seya T., Atkinson J.P. Functional properties of membrane cofactor protein of complement. Biochem. J. 264:1989;581-588.
36. Seya T., Okada M., Matsumoto M., Hong K., Kinoshita, Atkinson J.P. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP). Mol. Immunol. 28:1991;1137-1147.
37. Thomas D.J., Lublin D.M. Identification of 5′-flanking regions affecting the expression of the human decay-accelerating factor gene and their role in tissue-specific expression. J. Immunol. 150:1993;151-158.
38. Turpen T.H., Griffith P.M. Rapid isolation of RNA by a guanidium isothiocyanate/cesium chloride gradient method. Biotechniques. 4:1986;11-13.
39. Verga L., Frangione B., Tagliavini F., Giaccone G., Migheli A., Bugiani O. Alzheimer patients and Down patients: Cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neurosci. Lett. 105:1989;294-299.
40. Walker D.G., McGeer P.L. Complement gene expression in human brain: Comparison between normal and Alzheimer disease cases. Mol. Brain Res. 14:1992;109-116.
41. Wu E., Raine C.S. Multiple sclerosis: Interaction between oligodendrocytes and hypertrophic astrocytes and their occurrence in other, non-demyelinating conditions. Lab. Invest. 67:1992;88-99.
42. Wu E., Brosnan C.F., Raine C.S. SP-40,40 immunoreactivity in inflammatory CNS lesions displaying astrocyte/oligodendrocyte interactions. J. Neuropathol. Exp. Neurol. 52:1993;129-134.
43. Yang C., Jones J.L., Barnum S.R. Expression of decay-accelerating factor (CD55), membrane cofactor protein (CD46) and CD59 in the human astroglioma cell line, D54-MG, and primary rat astrocytes. J. Neuroimmunol. 47:1993;123-132.